Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

53
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
53
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

545
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
545
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

848
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
848
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

593
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
593
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

252
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
252
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

512
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
512

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Myocarditis and Genetic Susceptibility in Severe Paediatric Cardiomyopathy.

European journal of heart failure·2026
Same author

Sex differences in photon-counting computed tomography findings across hypertrophic phenotypes.

European heart journal. Imaging methods and practice·2026
Same author

Biomarkers in heart failure.

Advances in clinical chemistry·2026
Same author

Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis.

ESC heart failure·2026
Same author

Event rates in major Phase 3 heart failure trials over the last 20 years.

ESC heart failure·2026
Same author

Acoramidis for ATTR cardiomyopathy: value, access, and the duty to treat.

European heart journal. Quality of care & clinical outcomes·2026

Related Experiment Video

Updated: Oct 23, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.5K

Vericiguat for Heart Failure with Reduced Ejection Fraction.

Carlo Mario Lombardi1, Giuliana Cimino2, Matteo Pagnesi2

  • 1Cardiology; ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, P.zza Spedali Civili 1, 25123, Brescia, Italy. lombardi.carlo@alice.it.

Current Cardiology Reports
|August 19, 2021
PubMed
Summary

Soluble guanylate cyclase (sGC) stimulators like vericiguat show promise for high-risk heart failure (HF) patients. Vericiguat may reduce cardiovascular death and HF hospitalizations in patients with HF and reduced ejection fraction (HFrEF).

Keywords:
Cyclic guanosine monophosphateHeart failurePathophysiologySoluble guanylate cyclaseTreatmentVericiguat

More Related Videos

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:42

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

173
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

518

Related Experiment Videos

Last Updated: Oct 23, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.5K
Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction
06:42

Echocardiography-guided Injection for Targeted and Reliable Intramyocardial Stem Cell Delivery in a Rat Model of Myocardial Infarction

Published on: July 25, 2025

173
Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

518

Area of Science:

  • Cardiovascular medicine
  • Pharmacology

Background:

  • The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is crucial for cardiovascular regulation but is impaired in heart failure (HF).
  • In HF, reduced NO bioavailability and altered sGC redox state diminish NO responsiveness, compromising cardioprotection.

Purpose of the Study:

  • To review the role of the NO-sGC-cGMP pathway in heart failure.
  • To evaluate the therapeutic potential of sGC modulators, including activators and stimulators, in managing HF.

Main Methods:

  • Review of clinical trials and pharmacological mechanisms of sGC activators and stimulators.
  • Analysis of data on vericiguat's efficacy in high-risk heart failure patients.

Main Results:

  • sGC activators (e.g., cinaciguat) increase cGMP independently of NO but carry a risk of hypotension.
  • sGC stimulators (e.g., vericiguat, riociguat) enhance sensitivity to endogenous NO, offering a more physiological approach.
  • Vericiguat demonstrated a reduced incidence of cardiovascular death or HF hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF).

Conclusions:

  • Vericiguat may be a valuable addition for select high-risk HFrEF patients, particularly those prone to HF hospitalization.
  • Targeting the NO-sGC-cGMP pathway with stimulators like vericiguat represents a promising therapeutic strategy in heart failure management.